Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-12-05
2010-02-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S140100, C424S141100, C424S143100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
07666421
ABSTRACT:
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5397703 (1995-03-01), De Boer et al.
patent: 5476786 (1995-12-01), Huston
patent: 5514548 (1996-05-01), Krebber et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5562903 (1996-10-01), Co et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5622701 (1997-04-01), Berg
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5869050 (1999-02-01), de Boer et al.
patent: 5919449 (1999-07-01), Dinsmore
patent: 5977318 (1999-11-01), Linsley et al.
patent: 6084067 (2000-07-01), Freeman et al.
patent: 6096537 (2000-08-01), Chappel
patent: 6130316 (2000-10-01), Freeman et al.
patent: 6280957 (2001-08-01), Sayegh et al.
patent: 6346248 (2002-02-01), De Boer et al.
patent: 6605279 (2003-08-01), Freeman et al.
patent: 6608180 (2003-08-01), Sharpe et al.
patent: 6827934 (2004-12-01), Co et al.
patent: 6913747 (2005-07-01), Co et al.
patent: 6972125 (2005-12-01), Co et al.
patent: 6984383 (2006-01-01), Co et al.
patent: 0 120 694 (1984-10-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 194 276 (1986-09-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 519 596 (1992-12-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO94/01547 (1994-01-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO95/03408 (1995-02-01), None
patent: WO95/34320 (1995-12-01), None
patent: WO96/14865 (1996-05-01), None
patent: WO98/19706 (1998-05-01), None
patent: WO 00/19706 (2000-04-01), None
Bird et al., Single-chain Antigen-binding Proteins, Science, 242:423-426 (1988).
Hathcock et al., “Identification of an alternative CTLA-4 ligand costimulatory for T cell activation,” Science 262:905-907 (1993).
Kammann et al., Rapid Insertional Mutagenesis of DNA by Polymerase Chain Reaction (PCR), Nucl. Acids Res. 17:5405 (1989).
Kaufman et al., “Improved Vectors for Stable Expression of Foreign Genes in Mammalian Cells by Use of the Untranslated Leader Sequence from EMC Virus,” Nucl. Acids Res., 19:4485-4490 (1991).
Kettleborough et al., “Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation,” Protein Engineering, 4:773-783 (1991).
Kolbinger et al., “Humanization of a Mouse Anti-Human IgE Antibody: A Potential Therapeutic for IgE-Mediated Allergies,” Protein Engineering, 6(8):971-980 (1993).
NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, Gl121042 (Jul. 21, 1986).
Saltus, Richard, “Drug allows transplants of mismatched bone marrow,” The Boston Globe, A1 (Jun. 3, 1999).
Sato et al., “Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth,” Cancer Research, 53:851-856 (1993).
Chen et al., “Enhancement and Destruction of Antibody Function by Somatic Mutation; Unequal Occurrence is Controlled by V Gene Combinatorial Associations,” The EMBO Journal, 14:2784-2794 (1995).
Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology, 145:33-36 (1994).
Kussie et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J. Immunol., 152:146-152 (1994).
Lund et al., “Multiple Interactions of IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human FCγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains,” J. Immunol. , 157:4963-4969 (1996).
Rudikoff et al., “Single Amino Acid Substitution Altering Antigen-Binding specificity,” PNAS 79:1979-1983 (1982).
Alegre et al., “Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors,” Digestive Diseases and Sciences, 40(1):58-64 (1995).
Azuma et al., “B70 antigen is a second ligand for CTLA-2 and CD28,” Nature, 366:76-79 (1993).
Berzofsky et al., “Antigen-Antibody Interaction,” In Fundamental Immunology, W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984).
Bluestone, J.A., “Costimulation and its role in organ transplantation,” Clinical Transplantation, 10:104-109 (1996).
Bree et al., “Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps vitrus vaccine,” Blood, 94(10) Suppl. 1 part 1, p. 439a (1999).
Chen et al., “Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4,” Cell, 71:1093-1102 (1992).
Cole et al., “Human IgG2 Variants of Chimeric Anti-CD3 are Nonmitogenic to T cells,” The J. of Immunology, 159:3613-3621 (1997).
Co et al., “Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen,” The J. of Immunology, 148(4):1149-1154 (1992).
Co et al., “Humanized Antibodies for Antiviral Therapy,” Proc. Natl. Acad. Sci. USA, 88:2869-2873 (1991).
Cromwell et al., Abstract: “The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation,” Experimental Biology 98 Meeting, Apr. 22, 1998.
Daikh et al., “The CD28-B7 costimulatory pathway and its role in autoimmune disease,” J. of Leukocyte Biol., 62:156-162 (1997).
Damico et al., “Pharmacokinetics of IV Adminstered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomoglus Monkeys,” Abstract, 17th Annual Scientific Meeting, Jan. 9, 1998.
Ellison et al., “Linkage and sequence homology of two human immunoglobulin in γ heavy chain constant region genes,” Proc. Natl. Acad. Sci. USA, 79:1984-1988 (1982).
Engel et al., “The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes is the CD86 Differentiation antigen,” Blood, 84(5):1402-1407 (1994).
Fleischer et al., “Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes,” Immunology, 89:592-598 (1996).
Fujihara et al., “Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity,” Blood 87(6):2386-2393 (1996).
Genes IV, Benjamin Lewin , Oxford University Press, 1990, p. 810.
Glaser et al., “Dissection of the Combining Site in a Humanized Anti-Tac Antibody,” The J. of Immunology, 149(8):2607-2614 (1992).
Hathcock et al., “Role of the CD28-B7 costimulatory pathways in T cell-dependent B cells responses,” Advances in Immunology, 62:131-166 (1996).
He et al., “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selection,” The J. of Immunology, 160:1029-1035 (1998).
Jeannin et al., “CD86 (B7-2) on Human B Cells,” The J. of Biol. Chemistry, 272(25):15613-15619 (1997).
Jefferis et al., “Molecular characterization of IgG antibody effector sites,” Department of Immunol., The Medical School, Edgbaston, Birmingham, pp. 115-126.
Lenschow et al., “Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in
Carreno Beatriz
Celniker Abbie Cheryl
Co Man Sung
Collins Mary
Goldman Samuel
Foley & Hoag LLP
Gambel Phillip
Genetics Institute LLC
LandOfFree
Methods of treatment of autoimmune diseases using humanized... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment of autoimmune diseases using humanized..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment of autoimmune diseases using humanized... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178669